NCT05385263 2022-05-26
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
Clinical Trials
8 trialsNCT05286164 2022-04-15
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT05164770 2021-12-21
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
Shandong Provincial Hospital
Phase 3 Unknown
NCT04152577 2019-11-05
R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
Shandong Provincial Hospital
Phase 4 Unknown
NCT03569696 2019-04-23
NivoM
Sheba Medical Center
Phase 2 Unknown
NCT03881761 2019-03-21
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Henan Cancer Hospital
Phase 1 Unknown
NCT03881774 2019-03-21
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Henan Cancer Hospital
Phase 1 Unknown
NCT02996617 2016-12-19
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
Shandong Provincial Hospital
Phase 4 Unknown